Skip to main content

Andersen Eric's Form 4 filing

Merrimack Pharmaceuticals Inc (MACK) · filed Feb 1, 2023

Accession no.
0000899243-23-003115
Filed
Feb 1, 2023, 4:05 PM ET
Trade date
Jan 30-31, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $306.1K. It was filed 2 days after the trade.

This filing was later replaced by the amendment 0000899243-23-006607 (Mar 1, 2023). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Andersen EricCIK 0001517667Director, Other: See remarks
Western Standard Partners LPCIK 0001450414Other: See Remarks
Western Standard LLCCIK 0001517666Other: See Remarks
Western Standard Partners QP, L.P.CIK 0001544857Other: See Remarks

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 30, 2023Common StockPPurchaseAcquired+19,750$11.36+$224,312.61,282,853Indirect
Jan 30, 2023Common StockPPurchaseAcquired+4,958$11.36+$56,310.98323,856Indirect
Jan 31, 2023Common StockPPurchaseAcquired+1,782$11.40+$20,314.441,284,635Indirect
Jan 31, 2023Common StockPPurchaseAcquired+450$11.40+$5,129.91324,306Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)